Don't Use the New Oral Antiplatelet Drug Zontivity Alone

September 2014

You'll hear controversy about the new oral antiplatelet drug, Zontivity ( zon-TIV-i-tee, vorapaxar).

It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.

It's approved for use with low-dose aspirin and/or clopidogrel after an MI or in patients with peripheral artery disease...to further reduce CV events or death.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology Save Niacin for Special Situations
Statins Point Out Statins' CV Benefits STILL Outweigh Diabetes Risk
Vaccines Give Intranasal FluMist to Young, Healthy Children
Depression Use Low Antipsychotic Doses When Adding to an Antidepressant
Smoking Cessation Save Combos with Chantix for When Other Options Don't Work
E-Prescriptions Send E-Rxs at the End of Each Patient Visit
Diuretics Don't Rely on Potassium from Foods to Treat Hypokalemia
Infectious Diseases Warn About the High Cost of Some Cold Sore Treatments
Oral Health Explain Electric Toothbrushes Can Reduce Plaque More Than Manual Brushes
Antithrombotics Don't Use the New Oral Antiplatelet Drug Zontivity Alone
ADHD Don't Do an ECG Before Beginning Stimulant in Most Kids
Med Administration Dilute Liquid Meds Before Enteral Tube Administration
Opioids DEA's switch of all hydrocodone COMBOS (Vicodin, Tussionex, etc) from Schedule III to Schedule II on October 6 will cause confusion

Don't Use the New Oral Antiplatelet Drug Zontivity Alone

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents